Sichenzia Ross Ference Carmel LLP represents Calidi Biotherapeutics, Inc. in a $2.05 Million Registered Direct Offering and Concurrent Private Placement

Press Release – New York, NY – October 23, 2024 – Sichenzia Ross Ference Carmel LLP announced today that it represented Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, in a $2.05 million registered direct offering and concurrent private placement. The gross proceeds, before deducting the placement agent fees and other offering expenses payable by the Company, were approximately $2.05 million.

The SRFC team was led by partner Jay Yamamoto and associate Rohini Sud.